MENU
Home
Add Document
Sign In
Create An Account
PDF Reader
Full Text
The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY COLLEGE LONDON on June 28, 2018. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights reserved.
The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY COLLEGE LONDON on June 28, 2018. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights reserved.
The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY COLLEGE LONDON on June 28, 2018. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights reserved.
The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY COLLEGE LONDON on June 28, 2018. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights reserved.
The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY COLLEGE LONDON on June 28, 2018. For personal use only. No other uses without permission. From the NEJM Archive. Copyright © 2010 Massachusetts Medical Society. All rights reserved.
Suggest Documents
Polymyositis and dermatomyositis (first of two parts).
Gastrin (second of two parts).
Histamine (second of two parts).
Polymyositis and dermatomyositis: clinical problems.
dermatomyositis.
dermatomyositis: the current position.
Lung defense mechanisms (second of two parts).
Bronchodilator therapy (second of two parts).
Renal transplantation (second of two parts).
Clinical pharmacokinetics (second of two parts).
Nailfold capillaroscopic changes in dermatomyositis and polymyositis.
Plasma exchange in polymyositis and dermatomyositis.
Risk of cancer in dermatomyositis or polymyositis.
Intravenous immunoglobulin for polymyositis and dermatomyositis.
Polymyositis, dermatomyositis and inclusion-body myositis.
Dystrophin abnormalities in polymyositis and dermatomyositis.
Catecholamines and neurologic diseases (second of two parts).
Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis.
Cyclosporin in the management of polymyositis and dermatomyositis.
Clinical pharmacology of oral antidiabetic agents (second of two parts).
Vasodilator therapy of cardiac failure (second of two parts).
Prevalence and incidence of polymyositis and dermatomyositis in Japan.
The pathogenesis of atherosclerosis (second of two parts).
Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone.
Polymyositis and dermatomyositis (second of two parts).
The New England Journal of Medicine Downloaded from nejm.org at UNIVERSITY COLLEGE LONDON on June 28, 2018. For personal use only. No other uses witho...
882KB Sizes
0 Downloads
0 Views
Download PDF
Recommend Documents
Polymyositis and dermatomyositis (first of two parts).
Gastrin (second of two parts).
Histamine (second of two parts).
Polymyositis and dermatomyositis: clinical problems.
dermatomyositis.
dermatomyositis: the current position.
Lung defense mechanisms (second of two parts).
Bronchodilator therapy (second of two parts).
Renal transplantation (second of two parts).
Clinical pharmacokinetics (second of two parts).
×
Sign In
Login with Facebook
Don't have an account?
Forgot Password?
×
Sign Up
By clicking register, I agree to your terms